Publications by authors named "R Caparica"
Article Synopsis
- Canakinumab, a monoclonal antibody targeting IL-1β, was tested in a phase III study (CANOPY-1) to see if it could improve survival rates in patients with advanced non-small-cell lung cancer (NSCLC) when combined with pembrolizumab and chemotherapy.
- The study involved 643 patients split between canakinumab and placebo groups, with results showing no significant difference in progression-free survival (PFS) or overall survival (OS) after a median follow-up of 21.2 months.
- While safety profiles were similar, canakinumab treatment led to delays in worsening symptoms like chest pain, coughing, and shortness of breath, suggesting it might
Purpose: To assess whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer (EBC).
Methods: ALTTO (NCT00490139) patients were categorized by ESA use during adjuvant anti-HER2 treatment. Disease-free-survival (DFS), overall survival (OS), and time-to-distant recurrence (TTDR) were analyzed by ESA administration, with subgroup analyses according to prognostic factors.
Background: Patients with small node-negative HER2-positive breast cancer are commonly treated with paclitaxel and 1 year of adjuvant trastuzumab. We performed a sub-analysis of the ALTTO trial to explore the long-term outcomes of patients with small node-negative tumours.
Methods: The ALTTO trial randomised 8381 patients with early HER2-positive BC treated with adjuvant chemotherapy (anthracycline/taxane- or taxane/carboplatin-based), to trastuzumab (T), lapatinib (L), their sequence (T → L) or their combination (L + T).
Background: Beta-2 adrenergic receptor (ß2AR) modulates immune activation and may enhance trastuzumab activity. We assessed the impact of ß2AR gene (ADRB2) expression on the outcomes of patients with HER2-positive early-stage breast cancer enrolled on the NCCTG-N9831 trial.
Patients And Methods: This is a post-hoc analysis of the NCCTG-N9831 trial, which compared chemotherapy (arm A) versus chemotherapy plus trastuzumab (arms B&C) as adjuvant treatment of patients with HER2-positive early-stage breast cancer, with disease-free survival (DFS) as primary endpoint.